- Home
- YI vs IKNA Comparison
YI vs IKNA Comparison
Compare YI & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- IKNA
- Stock Information
- Founded
- YI 2010
- IKNA 2016
- Country
- YI China
- IKNA United States
- Employees
- YI N/A
- IKNA N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- IKNA Health Care
- Exchange
- YI Nasdaq
- IKNA Nasdaq
- Market Cap
- YI 70.0M
- IKNA 61.8M
- IPO Year
- YI N/A
- IKNA 2021
- Fundamental
- Price
- YI $7.09
- IKNA $1.34
- Analyst Decision
- YI
- IKNA Strong Buy
- Analyst Count
- YI 0
- IKNA 1
- Target Price
- YI N/A
- IKNA $4.00
- AVG Volume (30 Days)
- YI 11.9K
- IKNA 71.8K
- Earning Date
- YI 06-19-2025
- IKNA 08-07-2025
- Dividend Yield
- YI N/A
- IKNA N/A
- EPS Growth
- YI N/A
- IKNA N/A
- EPS
- YI N/A
- IKNA N/A
- Revenue
- YI $1,984,717,013.00
- IKNA N/A
- Revenue This Year
- YI N/A
- IKNA N/A
- Revenue Next Year
- YI N/A
- IKNA N/A
- P/E Ratio
- YI N/A
- IKNA N/A
- Revenue Growth
- YI N/A
- IKNA N/A
- 52 Week Low
- YI $4.15
- IKNA $0.97
- 52 Week High
- YI $12.90
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- YI 34.00
- IKNA 54.06
- Support Level
- YI $6.65
- IKNA $1.31
- Resistance Level
- YI $7.80
- IKNA $1.37
- Average True Range (ATR)
- YI 0.47
- IKNA 0.05
- MACD
- YI -0.13
- IKNA -0.01
- Stochastic Oscillator
- YI 7.35
- IKNA 26.85
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.